East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Siponimod Tablets, 0.25mg, 1mg, and2 mg . Aurobindo Pharma’s Siponimod Tablets are an AB-rated generic equivalent to the reference listed drug (RLD), Mayzent®  Tablets manufactured by Novartis Pharmaceuticals Corporation.

Siponimod Tablets are indicated for:

• The treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.